Lundbeck Voluntarily Recalls Two Lots Of NeoProfen Due to Particulate Matter

Lundbeck Inc. July 30 announced that it has voluntarily recalled two lots of NeoProfen (ibuprofen lysine injection) that failed to meet a visible particulate quality requirement.

These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage, the company said. The NeoProfen recall includes product lots 1734991 (expiration date: April 2011) and 1922319 (expiration date: March 2012).

NeoProfen is a nonsteroidal anti-inflammatory therapy indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 grams and 1500 grams, who are no more than 32 ...